{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-063514","form_type":"8-K","ticker":"SNDX","cik":"0001395937","company_name":"Syndax Pharmaceuticals Inc","filed_at":"2025-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.153502+00:00","generated_at":"2026-05-22T16:54:39.283294+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Syndax Q1 Revuforj rev $20M, Niktimvo rev $13.6M; sNDA for mNPM1 AML","bullets":["Revuforj net revenue $20.0M in first full quarter; Niktimvo net revenue $13.6M (Incyte reported) in first partial quarter.","Submitted sNDA seeking Priority Review for revumenib in R/R mNPM1 AML under FDA RTOR program.","Initiated EVOLVE-2 pivotal frontline trial of revumenib + venetoclax/azacitidine in mNPM1 and KMT2Ar AML.","Net loss $84.8M ($0.98 per share) vs $72.4M ($0.85 per share) year ago; cash $602.1M.","Full-year 2025 R&D guidance $260-280M, total R&D+SG&A $415-435M; expects to reach profitability."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-063514","json":"https://secwatch.observer/filing/0000950170-25-063514.json","markdown":"https://secwatch.observer/filing/0000950170-25-063514.md","text":"https://secwatch.observer/filing/0000950170-25-063514.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1395937/000095017025063514/0000950170-25-063514-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1395937/000095017025063514/sndx-20250505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T16:54:39.283294+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}